MedTrace Logo

Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)

NCT07083089 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2025-12-09

No results posted yet for this study

Summary

The study aims to phenotype hearing in patients with early stage of neurodegenerative disorders to explore the prevalence of various hearing disorders in comparison to a control population. Specific focus is made on patients with speech-in-noise intelligibiltiy deficit despite normal tonal audiograms referred to as hidden hearing loss, with potential identification of associated biomarkers.

Conditions

  • Mild Cognitive Impairment (MCI) Amnestic
  • Parkinson Disease (PD)
  • Healthy Participants

Interventions

OTHER

Thorough Hearing assessment

Otoscopy Tympanometry Tonal audiometry (air and bone conduction) Vocal audiometry (in silence and in noise) Distorsion Products of OtoAcoustic Emissions (DPOAE) Middle Ear Muscle Reflex (MEMR) Auditory Brainstem Response (ABR) Electrocochleography (EcochG)

Sponsors & Collaborators

  • Cilcare SAS

    lead INDUSTRY

Principal Investigators

  • Mathieu SCHUE, PhD · Cilcare SAS

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-24
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07083089 on ClinicalTrials.gov